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Abstract
The use of growth hormone (GH) as an anabolic agent is lim-
ited by its tendency to cause hyperglycemia and by its inability
to reverse nitrogen wasting in some catabolic conditions. In a
previous study comparing the anabolic actions ofGH and IGF-
I (insulin-like growth factor I), we observed that intravenous
infusions of IGF-I (12 Mg/kg ideal body wt [IBWJ/h) atten-
uated nitrogen wasting to a degree comparable to GH given
subcutaneously at a standard dose of 0.05 mg/kg IBW per d.
IGF-I, however, had a tendency to cause hypoglycemia.
In the present study, we treated seven calorically restricted
(20 kcal/kg IBW per d) normal volunteers with a combination
of GH and IGF-I (using the same doses as in the previous
study) and compared its effects on anabolism and carbohydrate
metabolism to treatment with IGF-I alone. The GH/IGF-I
combination caused significantly greater nitrogen retention
(262±43 mmol/d, mean±SD) compared to IGF-I alone
(108±29 mmol/d; P < 0.001). GH/IGF-I treatment resulted
in substantial urinary potassium conservation (34±3 mmol/d,
mean±SE; P < 0.001), suggesting that most protein accretion
occurred in muscle and connective tissue. GH attenuated the
hypoglycemia induced by IGF-I as indicated by fewer hypogly-
cemic episodes and higher capillary blood glucose concentra-
tions on GH/IGF-I (4.3±1.0 mmol/liter, mean±SD) com-
pared to IGF-I alone (3.8±0.8 mmol/liter; P < 0.001). IGF-I
caused a marked decline in C-peptide (1,165±341 pmol/
liter; mean±SD) compared to the GH/IGF-I combination
(2,280±612 pmol/liter; P < 0.001), suggesting maintenance
of normal carbohydrate metabolism with the latter regimen.
GH/IGF-I produced higher serum IGF-I concentrations
(1,854±708 Mg/liter; mean±SD) compared to IGF-I only
treatment (1,092±503 Mg/liter; P < 0.001). This observation
was associated with increased concentrations of IGF binding
protein 3 and acid-labile subunit on GH/IGF-I treatment and
decreased concentrations on IGF-I alone.
These results suggest that the combination ofGH and IGF-
I treatment is substantially more anabolic than either IGF-I or
GH alone. GH/IGF-I treatment also attenuates the hypoglyce-
mia caused by IGF-I alone. GH/IGF-I treatment could have
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important applications in diseases associated with catabolism.
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Introduction
Patients with acute or chronic illnesses are often in negative
nitrogen balance despite adequate nutritional support (1-3).
Growth hormone (GH)' can cause a partial reversal of nitro-
gen wasting in humans who are catabolic because of surgery
(4), glucocorticoid treatment (5), chronic obstructive pulmo-
nary disease (6), or dietary restriction (7, 8). However, GH has
failed to improve nitrogen retention in some patients with sep-
sis (9) or burn injury (10). Furthermore, GH's tendency to
cause insulin resistance ( 11 ) worsens the glucose intolerance
associated with glucocorticoid therapy (5) or severe stress, such
as that caused by extensive surface bums (10).
Insulin-like growth factor-I (IGF-I), a peptide that medi-
ates the growth-promoting effects of GH ( 12, 13), has been
shown to reverse the catabolic effects of caloric restriction in
normal volunteers (14). In a study comparing the anabolic
actions ofGH with IGF-I (14), we observed that infusions of
IGF-I ( 12 Mg/kg per h) attenuate nitrogen wasting to a degree
comparable to a standard treatment dose ofGH (0.05 mg/kg
per d). IGF-I infusion, however, had a tendency to cause hypo-
glycemia despite substantial suppression ofinsulin. In contrast,
GH caused significant increases in both insulin and glucose
concentrations, consistent with an increase in insulin resis-
tance.
Based on these observations, we hypothesized that treat-
ment with a combination ofGH and IGF-I would ameliorate
the hypoglycemia caused by IGF-I given alone, and that com-
bined GH/IGF-I treatment would be more anabolic than ei-
ther hormone given alone. Therefore, we treated calorically
restricted normal volunteers with a combination of GH and
IGF-I, and compared its effects to IGF-I alone.
Methods
Study design. The seven normal volunteers (four men and three
women, ages 22-47 yr) who participated in this study were recruited by
advertisement and were within 10% of ideal body weight ( 15). They
were determined to be in good health by medical history, physical ex-
amination, and routine laboratory studies (complete blood count, elec-
trolytes, urea nitrogen, creatinine, uric acid, total protein, albumin,
total bilirubin, glucose, calcium, phosphorus, hepatic enzymes, lipid
1. Abbreviations used in this paper: ALS, acid-labile subunit of the
150-kD insulin-like growth factor binding protein complex; GH,
growth hormone; IBW, ideal body weight; IGF-I, insulin-line growth
factor I; IGFBP, IGF binding protein.
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profile, and urinalysis). The study was approved by the University of
North Carolina Institutional Committee for the Protection of the
Rights of Human Subjects, and informed consent was obtained from
each subject. The subjects were monitored on the General Clinical
Research Center of the University of North Carolina (Chapel
Hill, NC).
Subjects were permitted to continue most of their daily activities
outside the hospital but were asked to refrain from vigorous exercise.
During each of the two 2-wk diet periods, the subjects reported to the
General Clinical Research Center daily for weighing, blood drawing,
submission of 24-h urine collections, and consumption of meals. Dur-
ing weeks 1 and 2 ofthe study, each subject was fed a diet containing 20
kcal/kg IBW with 1 g protein/kg IBW. Nonprotein calories were pro-
vided as 50% carbohydrate and 50% lipid. The diet included 5 kcal/kg
per d of carbohydrate in the form ofjuice divided into three aliquots
and given at the hours of0600, 2000, and 2400 each day. The nutrient
content of the weighed food in each diet was determined from United
States Department ofAgriculture food tables ( 16). Dietary compliance
was monitored by weighing the food left after each meal and by observ-
ing the constancy of weight loss and urinary nitrogen excretion.
During the last 4 d of week 1 and each day of week 2, 24-h urines
were collected for urea nitrogen, creatinine, and potassium. During this
same interval morning blood samples were collected before breakfast
(0700 h) for glucose, urea nitrogen, electrolytes, creatinine, insulin,
C-peptide, IGF-I, IGF binding proteins (IGFBP) 1, 2, and 3 and the
acid-labile subunit (ALS) ofthe 1 50-kD IGF binding protein complex.
On day 4 ofweek 2, blood samples were collected at 0700, 1600, 1800,
2000, and 2400 h to assess the pharmacokinetics ofIGF-I. During week
2, subjects received one of two treatments: (a) daily intravenous infu-
sions of recombinant human IGF-I (gift from Genentech, Inc., South
San Francisco, CA) at a dose of 12 ,g/kg IBW per h for 16 h between
the hours of 1600 and 0800 for 5 d; or (b) combination of IGF-I (same
conditions as above) and daily subcutaneous injections ofrecombinant
human GH (Nutroping, gift from Genentech, Inc.) at a dose of 0.05
mg/kg IBW that was given at 1600 h for 5 d. On the sixth day, the
IGF-I infusion was given between 0800 and 2400 h, and the GH was
administered at 0800. At times, the IGF-I infusion rate had to be re-
duced temporarily because of hypoglycemia (e.g., blood glucose < 55
mg/dl). After week 2, the subjects were fed a normal diet for 3 wk.
During weeks 6 and 7, the diet restriction and treatment cycle that were
carried out in weeks 1 and 2 were repeated using the alternate treat-
ment. The sequence of the GH/IGF-I and IGF-I treatments was ran-
domized among the subjects.
Measurements. Body weight was recorded daily. 24-h urinary ex-
cretion of creatinine, urea nitrogen, and potassium were measured by
autoanalyzer (Hitachi 717; Boehringer Mannheim Diagnostic Lab
Systems, Indianapolis, IN, and Synchron CX3; Beckman Instruments,
Inc., Fullerton, CA). Urine collections for which the creatinine varied
by > 15% from the mean for an individual subject were omitted from
the analysis (2 of 154 collections were omitted). Daily nitrogen balance
was calculated by subtracting the sum of the urinary urea nitrogen
excretion and estimated stool and integument losses (245 mmol) from
the daily nitrogen intake ( 16). The nitrogen content of food not eaten
was subtracted from the total intake. Capillary blood glucose was mea-
sured during the IGF-I infusions at - 2-h intervals at the bedside
(Chemstrip BG, Accucheck II; Boehringer-Mannheim). Serum potas-
sium, glucose, urea nitrogen, and creatinine were measured by autoan-
alyzer (Synchron CX3; Beckman Instruments, Inc.).
IGF-I concentrations were measured by RIA after separating IGF-I
from IGF binding proteins using octadecasilyl-silica cartridges (C-1 8
Sep-Paks; Waters Associates, Millipore Corp., Milford, MA) ( 17 ). The
results were expressed as gg/liter after correcting for losses during ex-
traction. The intra- and interassay coefficients of variation for this as-
say were 6.1%. Serum insulin was measured by RIA ( 18), and serum
C-peptide was measured with a RIA kit (Incstar, Stillwater, MN). The
lower limit of detection for the insulin assay is 18 pmol/liter, and for
the C-peptide assay it is 92 pmol/liter. IGFBP-I and 2 were assayed by
disequilibrium RIA ( 19, 20). The lower limits of detection for the
IGFBP-1 and 2 assays are 2 and 0.2 ng/ml, respectively. The intra- and
interassay coefficients ofvariation for IGFBP-I were 9 and 15%, respec-
tively. The intra- and interassay coefficients of variation for IGFBP-2
were 6 and 10%, respectively. IGFBP3 concentrations were measured
by RIA using recombinant human IGFBP3 (gift from Genentech, Inc.)
as a standard. The antiserum was prepared from rabbits immunized
with human IGFBP3, as described previously for IGFBP1 (19). The
antiserum bound 50% of the radiolabeled IGFBP3 at a 1:20,000 dilu-
tion. '25I-IGFBP3 was prepared using a method described previously
(19) and had a specific activity of 125 gCi/ug. The lower limit of
detection is 1.0 ng/ml, and the intra- and interassay coefficients of
variation were 8 and 13%, respectively. ALS concentrations were mea-
sured by RIA as previously described (21 ). The lower limit ofdetection
is 0.5 Atg/ml.
All values were expressed as the mean±SD, except for urinary potas-
sium excretion, which was expressed as the mean±SE. The data were
analyzed for statistical significance by the paired t test using the Bon-
ferroni correction for repeated measurements. Unless otherwise stated,
means and standard deviations in Results were calculated for the last 4
d of each diet and treatment week.
Results
The subjects lost 3.1±1.2 (mean±SD) and 2.7±0.6 kg during
the week before IGF-I treatment and GH/IGF-I treatment,
respectively (P = NS). The mean nitrogen balance was
- 139±48 mmol/d (mean±SD) during the IGF-I pretreatment
week and -140±50 mmol/d during the GH/IGF-I pretreat-
ment week (P = NS).
Anabolic effects. During the IGF-I treatment period, nitro-
gen balance improved from a pretreatment mean of -139±48
to -31±29 mmol/d during the last 4 d of treatment (P
< 0.001; Fig. 1 ). GH/IGF-I treatment, however, induced entry
into positive nitrogen balance, from a pretreatment mean of
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Figure 1. Changes in nitrogen balance in response to infusion of IGF-I
(an) or combined treatment with GH and IGF-I (in). IGF-I was given
by continuous infusion ( 12 gg/kg IBW per h) for 16 h on days 8-12
between the hours of 1600 and 0800. On day 13, the infusion was
given between 0800 and 2400 hours. GH was given by subcutaneous
injection (0.05 mg/kg IBW) at 1600 h on days 8-12 and at 0800 on
day 13. Daily nitrogen balance was calculated by subtracting the sum
of the 24-h urinary urea nitrogen excretion and the estimate of stool
and integument losses (245 mmol) from the daily nitrogen intake.
The results are expressed as the mean±SD for seven subjects for the
last 4 d of each diet and treatment week. The differences in nitrogen
balance between treatment groups were significant (P < 0.01 ) on days
9-13.
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(P < 0.001). The improvement produced by the combination
was significantly greater than that produced by IGF-I alone (P
<0.001).
The improvements in nitrogen balance were accompanied
by decreases in serum urea nitrogen. From a pretreatment con-
centration of 5.54±0.93 mmol/liter (mean±SD), IGF-I treat-
ment decreased serum urea nitrogen to 2.35±0.44 mmol/liter
(P < 0.001). From a pretreatment mean of 5.63±1.08 mmol/
liter, GH/IGF-I treatment decreased serum urea nitrogen to
1.35±0.33 mmol/liter (P < 0.001). The mean value during
GH/IGF-I was significantly lower than that during IGF-I
alone (P < 0.001).
In keeping with changes in nitrogen balance, the GH/IGF-I
combination reduced urinary potassium excretion (pretreat-
ment 67±7 mmol/d vs. on treatment 33±3 mmol/d,
mean±SE; P < 0.001) (Fig. 2). With IGF-I alone, however,
urinary potassium excretion did not change (pretreatment
mean of 61±5 mmol/day vs. on treatment mean of 61±5
mmol/d). Serum potassium decreased on IGF-I alone, from a
pretreatment concentration of4.2±0.2 (mean±SD) to 3.8±0.3
mmol/liter (P < 0.001), and from 4.1±0.2 to 3.6±0.2 mmol/
liter on GH/IGF-I (P < 0.001) . The difference in serum potas-
sium between the treatment groups was significant (P
= 0.002).
Effects on IGF-I concentration. From a pretreatment con-
centration of 255±94 ,g/liter (mean±SD), serum IGF-I in-
creased to 1,092±503 ;ig/liter during IGF-I treatment (P
< 0.001) (Fig. 3). GH/IGF-I treatment produced an even
greater elevation in IGF-I concentration, from 273±106 to
1,854±708 jig/liter (P < 0.001). During the 8-h interval in
which IGF-I was not infused (0800-1600) on day 11, serum
IGF-I concentrations declined in both treatment groups
(1,114±483 to 769±633 jig/liter on IGF-I treatment and
1,841±637 to 1,568±622 jig/liter on GH/IGF-I treatment).
When the IGF-I infusion was resumed at 1600 h, steady state
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Figure 2. Changes in urinary potassium excretion in response to in-
fusion of IGF-I (ti) or combined treatment with GH and IGF-I (in).
IGF-I and GH were administered as indicated in the legend in Fig. 1.
Daily urinary potassium excretion was measured from 24-h urine
collections. The results are expressed as the mean±SE for seven sub-
jects for the last 4 d of each diet and treatment week. The differences
in urinary potassium excretion between treatment groups were sig-
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Figure 3. Changes in serum IGF-I concentration in response to GH/
IGF-I (. - e) or IGF-I (o - - - o) treatments. IGF-I and GH were
administered as indicated in the legend in Fig. 1. Blood samples for
measurement of IGF-I by RIA were collected at 0700, 1 h before the
end ofeach IGF-I infusion on days 9-13 and 7 h after the end ofthe
infusion on day 14. The results are expressed as the mean±SD for
seven subjects. The differences in IGF-I concentrations between
treatment groups were significant (P < 0.01 ) on days 11-14. Treat-
ment interval (W).
Effects on carbohydrate metabolism. Capillary blood glu-
cose concentrations measured every 2 h during IGF-I infusions
were consistently higher on GH/IGF-I (4.3±1.0 mmol/liter;
mean±SD) compared to IGF-I alone (3.8±0.8 mmol/liter) (P
< 0.001; Fig. 4). Furthermore, 17.3% of values fell below 3.05
mmol/liter (55 mg/dl) during IGF-I treatment, whereas only
8.1% were low during GH/IGF-I treatment. Euglycemia was
maintained better on the GH/IGF-I regimen compared to
IGF-I treatment. This was apparent even though the IGF-I
infusion had to be stopped or slowed several times during treat-
ment with IGF-I alone, whereas the GH/IGF-I subjects con-
tinued to receive a constant rate of infusion. A total of five
episodes of symptomatic hypoglycemia (tremulousness, light-
headedness, diaphoresis, and headache) occurred in four sub-
jects on IGF-I treatment compared to two episodes in two sub-
jects on GH/IGF-I treatment. Both episodes on GH/IGF-I
occurred during the first day of treatment. Morning (0700 h)
serum glucose concentrations (1-2 h after 1.7 kcal/kg of car-
bohydrate) were also higher during GH/IGF-I treatment
(5.7±0.7 mmol/liter; mean±SD) than during IGF-I alone
(4.3±1.1 mmol/liter; P < 0.001).
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Figure 4. Effect ofGH/IGF-I (- ) or IGF-I (m) treatments on capillary
glucose. Capillary glucose was measured every 2 h during the IGF-I
infusion by a reflectance meter (Accucheck II; Boehringer Mann-
heim). Each bar represents the mean±SD of 42 measurements. The
differences in capillary glucoses between treatment groups were sig-
nificant (P < 0.01 ) on days 9-12.
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Figure 5. Effect of GH/IGF-I(e- ) or IGF-I (o - - - o) treat-
ments on C-peptide concentrations. Blood samples for C-peptide
measurement by RIA were collected at 0700, 1 h before the end of
each IGF-I infusion on days 9-13 and 7 h after the end of the infusion
on day 14. The results are the mean±SD for seven subjects. The dif-
ferences in C-peptide concentrations between treatment groups were
significant on days 10-12. Treatment interval (S).
While receiving IGF-I alone, the pretreatment morning in-
sulin concentration decreased from 49.8±35.2 (mean±SD) to
16.6±12.7 pmol/liter (P < 0.001), and the pretreatment C-
peptide concentration fell from 2,721+1,228 (mean±SD) to
1,165+341 pmol/liter(P< 0.001, Fig. 5). DuringGH/IGF-I,
insulin decreased from a pretreatment mean of 44.9±26.8 to
33.4±16.7 pmol/liter (P = 0.04), and C-peptide declined from
a pretreatment mean of 2,923±1,039 to 2,280±612 pmol/liter
(P = 0.02; Fig. 5). The decreases in insulin and C-peptide
concentrations were significantly greater during IGF-I treat-
ment than during GH/IGF-I (P < 0.001 for C-peptide and P
= 0.001 for insulin).
Effects on IGFBPs and theALS ofthe 150-kD bindingpro-
tein complex. GH/IGF-I increased IGFBP3 from 4.54±1.20
(mean±SD) to 6.40±1.70 ,g/ml (P < 0.01), whereas IGF-I
suppressed IGFBP3 from a pretreatment mean of4.53± 1.10 to
2.85±1.22 ,ug/ml (P < 0.01; Fig. 6 A). The difference in
IGFBP3 concentration produced by each treatment was signifi-
cant (P < 0.001). IGFBP2 concentration increased on IGF-I
from 242±153 (mean±SD) to 497±268 ng/ml (P = 0.002),
whereas GH/IGF-I treatment resulted in no change in the
IGFBP2 concentration. IGF-I alone increased IGFBP1 from
68±20 (mean±SD) to 98±25 ng/ml (P < 0.001), whereas
GH/IGF-I suppressed IGFBP1 (76±20 pretreatment to 65±8
ng/ml; P = 0.02). The difference between the two treatment
groups was significant (P < 0.001).
IGF-I alone suppressed ALS from a pretreatment concen-
tration of33±12 (mean±SD) to 19±10,gg/ml (P = 0.001; Fig.
6 B), whereas GH/IGF-I maintained ALS concentration
(32±10,gg/ml pretreatment to 40±13,gg/ml; P = 0.07). The
difference in ALS concentration produced by each treatment
was significant (P < 0.001).
Side effects. No significant adverse effects were observed
during either the IGF-I or GH/IGF-I treatments. Six of the
seven subjects reported discomfort over the area ofthe parotid
glands during both treatments. Only one subject developed pal-
pable enlargement ofthese glands, however, the serum amylase
remained normal. Six subjects during GH/IGF-I treatment
and four subjects during IGF-I treatment developed periorbital
edema. One subject developed pitting edema in the extremities
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Figure 6. Effect of GH/
IGF-I or IGF-I treat-
ments on (A) IGFBP3
and (B) ALS concen-
trations. Blood samples
were obtained at 0700,
1 h before the end of
each IGF-I infusion on
days 9-13 and 7 h after
the end ofthe infusion
on day 14. IGFBP3 and
ALS concentrations
were determined by
RIA. The results are ex-
pressed as the
mean±SD for seven
subjects for the last 3 d
ofeach diet and treat-
ment week. The differ-
ences in IGFBP3 and
ALS between treatment
groups were significant
(P <0.0l) on days 1 1-
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subjects gained 0.5±0.9 kg (mean±SD) on IGF-I alone and
2.1 ± 1.7 kg onGH/IGF-I. The proportion ofweight gain attrib-
utable to fluid retention or nitrogen accretion could not be
determined because sodium balance was not analyzed. Most of
the edema and all parotid tenderness resolved in every subject
within 3 d after discontinuing treatment.
Discussion
Our results show that the combination ofGH and IGF-I treat-
ment in calorically restricted humans is substantially more an-
abolic than either GH or IGF-I alone. The nitrogen retention
induced by the GH/IGF-I combination was 2.4-fold greater
than IGF-I alone (56±9 vs. 23±7%). Compared to results from
our previous study (14), in which the effects ofGH and IGF-I
were analyzed individually, the GH/IGF-I combination
caused 2.1-fold greater nitrogen retention than GH alone
(56±9 vs. 26±8%). We consider the present experiments com-
parable to our previous study (14) because subject characteris-
tics, study design, and GH and IGF-I doses were identical to
the present study, and the responses in the each of the two
studies to IGF-I alone were nearly identical.
The mean increase in nitrogen retention of 260 mmol/d
caused byGH / IGF-I treatment is greater than that achieved in
any previous trial using GH alone in catabolic subjects. Ward
et al. treated postoperative gastrointestinal patients with GH
(0.1 mg/kg per d) for 6 d and observed a mean increase in
nitrogen retention of 127 mmol/d compared to placebo (4). In
patients with chronic obstructive pulmonary disease, GH (0.05
mg/kg per d) caused a mean increase in nitrogen retention of
158 mmol/d compared to control (6). When obese subjects
were calorically restricted (12 kcal/kg IBW per d) and treated
with GH (0.1 mg/kg IBW every other day) for 5 wk, the mean
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nitrogen retention improved by 128 mmol/d compared to pla-
cebo (22). Marcus et al. treated normal elderly subjects with
GH (0.06 mg/kg per d) for 7 d and observed a mean increase
in nitrogen retention of 193 mmol/d (23). The magnitude of
nitrogen conservation in each ofthese trials ofGH falls short of
that which we observed with GH plus IGF-I.
Although a GH dose-response was observed in the study in
elderly subjects (23), it is doubtful that higher doses of GH
would have produced increases in nitrogen retention in cata-
bolic patients that were equal to that caused by GH plus IGF-I.
In obese, diet-restricted subjects, doubling the standard GH
treatment dose to 0.1 mg/kg IBW per d caused only a 10%
improvement in nitrogen retention (22, 24). Manson and Wil-
more (8) observed a mean increase in nitrogen retention of 179
mmol/d in calorically restricted normal volunteers given high
dose GH (0.14 mg/kg per d). More recently, Zeigler et al.
reported an increase of 201 mmol/d in subjects receiving a
high dose ofGH (0.18 mg/kg per d) along with hyperalimenta-
tion therapy (25).
During catabolism a significant portion of the nitrogen ex-
creted is derived from increased turnover of visceral protein.
Since 83% of the total body potassium is contained in muscle
and connective tissue compartments (26, 27), measurement of
potassium balance is considered to be a good index of protein
accretion in these compartments. We observed a marked de-
cline in urinary potassium excretion on GH/IGF-I treatment
suggesting that most nitrogen accretion occurred in muscle and
nonvisceral protein. The failure of potassium excretion to de-
cline during treatment with IGF-I alone might be the result ofa
less pronounced anabolic effect of IGF-I on muscle and non-
visceral protein accretion or a direct enhancement of renal po-
tassium secretion that counterbalanced a positive effect ofIGF-
I on potassium accretion.
In a previous study (28), IGF-I infusions of 32 ag/kg per h
in healthy volunteers on a normal diet were reported to cause
hypoglycemia. However, when the IGF-I dose was lowered to
20 Ag/kg per h, hypoglycemia did not occur (28). In contrast,
we previously showed that an IGF-I infusion of only 12 ag/kg
per h in calorically restricted humans caused hypoglycemia
despite the fact that insulin levels were suppressed three- to
fourfold (14). These observations suggest that catabolic sub-
jects, who may have decreased caloric intake or increased sub-
strate utilization, might be more sensitive than normal subjects
to the hypoglycemic effects of IGF-I. Addition ofGH to the
treatment regimen attenuated the hypoglycemia despite the
fact that the GH/IGF-I combination produced higher serum
IGF-I concentrations than those on IGF-I treatment alone.
This protective effect ofGH may have resulted from the higher
IGFBP3 concentrations, sequestering IGF-I and preventing its
rapid efflux from the-circulation (29). Another explanation
might be that GH's tendency to cause insulin resistance coun-
teracts the hypoglycemic effect of IGF-I ( 11). Conversely, the
hyperglycemia and hyperinsulinemia associated with GH
treatment alone were prevented by the combination treatment,
suggesting that IGF-I counteracts GH-induced glucose intoler-
ance ( 14).
Several mechanisms might explain the greater anabolic ef-
fect of the GH/IGF-I combination. First, GH/IGF-I treat-
ment caused markedly higher serum IGF-I concentrations
than IGF-I alone, possibly producing higher concentrations of
IGF-I in tissues. Second, the addition of GH to IGF-I treat-
ment reversed the insulin suppressive effect of IGF-I. These
higher insulin concentrations could enhance the anabolic ef-
fect of IGF-I, since insulin inhibits proteolysis (30, 31 ). Third,
GH and IGF-I may each affect protein balance by different
mechanisms. For example, GH administered to normal volun-
teers causes an increase in protein synthesis but does not signifi-
cantly inhibit proteolysis (5). In contrast, the predominant
mechanism that mediates the response to IGF-I infusion ap-
pears to be inhibition ofproteolysis (30). Fourth, the induction
of IGFBP3 and ALS by the GH/IGF-I combination might
account for a more stable IGF-I pool, which in turn might
provide more anabolic effect. IGFBP3 is the major carrier pro-
tein of IGF-I in serum (32), and its association with IGF-I and
ALS in a 1 50-kD ternary complex (33) increases the half-life of
IGF-I by more than 50-fold (34). In humans and hypophysec-
tomized rats, GH induces IGFBP3 and ALS (35-37). Forma-
tion of the ternary complex in response to GH is likely to have
facilitated stabilization of the IGF-I pool in the GH/IGF-I
treatment group. In contrast, infusion of only IGF-I lowered
IGFBP-3 and ALS, and is thereby likely to have caused a de-
crease in stability of IGF-I in the circulation. This effect might
have resulted from suppression of GH secretion by IGF-I, al-
though GH was not measured in this study. Stabilization of
IGF-I during GH/IGF-I treatment may have allowed periph-
eral tissues to be exposed continuously to higher concentra-
tions of IGF-I.
Insulin and IGF-I have qualitatively similar metabolic and
anabolic effects in that both decrease serum glucose and inhibit
proteolysis (30, 38). Since the mechanism of IGF-I action is
unknown, we cannot rule out the possibility that the anabolic
effects of IGF-I observed in this study might be mediated by an
insulin-like mechanism.
Although treatment with GH/IGF-I and IGF-I alone
caused fluid retention and parotid tenderness, these side effects
were transient and well-tolerated. The fluid retention can prob-
ably be explained by the fact that both GH and IGF-I decrease
renal sodium excretion and increase water reabsorption ( 13,
23, 39, 40). Parotid tenderness with intravenous IGF-I admin-
istration was observed in our previous study ( 14) and has been
described by other investigators (Lowry, S. F., personal com-
munication), however the cause ofthis effect is unknown. The
hypoglycemia associated with the GH/IGF-I combination oc-
curred mostly on the first day oftreatment and may have been
prevented entirely by administration of GH before initiating
the IGF-I infusion. This strategy would be based on the obser-
vation that C-peptide concentrations initially declined and
then recovered on the second day of GH/IGF-I treatment,
suggesting that the insulin resistance induced by GH was de-
layed by 24-48 h.
Our results in this diet restriction, catabolic model suggest
that the combination of GH/IGF-I could have important ap-
plications in diseases associated with catabolism. Since a vari-
ety of illnesses lead to either suppression ofappetite or reduced
nutrient absorption, therapy with GH and IGF-I could shorten
the convalescent phase. Patients with extensive surface burns
or sepsis have been reported to be refractory to GH (9, 10).
The combination ofGH and IGF-I could potentially be more
effective in such patients. Maintenance ofnormal glucose toler-
ance by the GH/IGF-I combination suggests that treatment
with both of these agents might be safer than IGF-I alone in
patients who are predisposed to hypoglycemia because of re-
duced caloric intake. Finally, the hyperglycemia that some-
times develops in response to GH administration may be ame-
Anabolic Effects ofGrowth Hormone and Insulin-like Growth Factor I 395
liorated by the combination therapy since the IGF-I dose could
be used to adjust blood glucose. The challenge for the future is
to determine whether this combination has efficacy in disease
states that are known to result in significant catabolism.
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